A Phase 3, Open-Label, Single-Arm Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of MK-8228 (Letermovir) for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Letermovir (Primary) ; Letermovir (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 21 Oct 2022 Status changed from active, no longer recruiting to completed.
- 20 Sep 2022 Planned End Date changed from 28 Nov 2022 to 6 Oct 2022.
- 20 Sep 2022 Planned primary completion date changed from 31 Oct 2022 to 6 Oct 2022.